Public health weekly report · 2026
Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim TaeYong, Lee Jae Seung, Jeong Oeuk, Lee Jeong Gyu, Choi Seungmi, Ryou Sangmi, Go MinJin, Kim Jungyeon
Аннотация
OBJECTIVES: The Korea hepatitis B cohort study is a prospective cohort established to analyze the epidemiological characteristics and treatment outcomes of individuals with chronic hepatitis B virus (HBV) infection in the Republic of Korea (ROK). This study aims to provide evidence to support HBV control, prevention strategies, and national policy development.
METHODS: Adults aged ≥19 years with chronic hepatitis B were enrolled at five regional medical institutions across ROK. Additional blood samples were collected from participants who consented to biospecimens donation. This prospective observational study did not interfere with routine clinical care. Data on antiviral treatment, treatment continuation, and liver-related outcomes, including hepatocellular carcinoma, were collected.
RESULTS: Between 2015 and 2024, a total of 3,221 participants were enrolled in the study. After excluding 422 individuals who were lost to follow-up, clinical data from 2,799 participants were collected. On average, 4.2 longitudinal blood samples per participant were obtained at 6- to 12-month intervals. The cohort exhibited epidemiological patterns consistent with previously reported trends in the ROK. The use of effective antiviral therapy was associated with better management of chronic hepatitis B.
CONCLUSIONS: The continuation of this study will enable systematic and efficient monitoring of the current status and long-term clinical outcomes of patients with chronic hepatitis B. These findings are expected to inform revisions of national clinical practice guidelines and support the development of public health policies in the ROK.
METHODS: Adults aged ≥19 years with chronic hepatitis B were enrolled at five regional medical institutions across ROK. Additional blood samples were collected from participants who consented to biospecimens donation. This prospective observational study did not interfere with routine clinical care. Data on antiviral treatment, treatment continuation, and liver-related outcomes, including hepatocellular carcinoma, were collected.
RESULTS: Between 2015 and 2024, a total of 3,221 participants were enrolled in the study. After excluding 422 individuals who were lost to follow-up, clinical data from 2,799 participants were collected. On average, 4.2 longitudinal blood samples per participant were obtained at 6- to 12-month intervals. The cohort exhibited epidemiological patterns consistent with previously reported trends in the ROK. The use of effective antiviral therapy was associated with better management of chronic hepatitis B.
CONCLUSIONS: The continuation of this study will enable systematic and efficient monitoring of the current status and long-term clinical outcomes of patients with chronic hepatitis B. These findings are expected to inform revisions of national clinical practice guidelines and support the development of public health policies in the ROK.